Suppr超能文献

低放射性碘消融治疗甲状腺乳头状癌患者的长期结果及术后非刺激状态下甲状腺球蛋白的预测价值

Long-term results of ablation with low radioiodine activity in patients with papillary thyroid carcinoma and predictive value of postoperative nonstimulated thyroglobulin.

作者信息

Rosario Pedro W, Mourão Gabriela F, Calsolari Maria R

机构信息

aPostgraduation Program bPostgraduation Program and Endocrinology Service, Santa Casa of Belo Horizonte, Minas Gerais, Brazil.

出版信息

Nucl Med Commun. 2016 Oct;37(10):1024-9. doi: 10.1097/MNM.0000000000000562.

Abstract

AIM

This study evaluated the long-term results of ablation with low iodine-131 (131I) activity in patients with papillary thyroid carcinoma (PTC) with a lower risk of recurrence and who remained with nonstimulated thyroglobulin (Tg) of at least 0.3 ng/ml after total thyroidectomy.

METHODS

This was a prospective study including 119 patients with PTC (except for microcarcinoma restricted to the thyroid and tumor with extensive extrathyroidal extension, aggressive histology, extensive lymph node involvement, or known residual disease). After thyroidectomy, all patients had nonstimulated Tg of at least 0.3 ng/ml (range: 0.3-8.5 ng/ml). The patients were treated with low 131I activity (30 or 50 mCi).

RESULTS

Post-therapy whole-body scanning showed ectopic uptake in two patients. When evaluated 12 months after ablation, nonstimulated Tg up to 0.2 ng/ml with negative antithyroglobulin antibodies and neck ultrasonography, defined as excellent response to initial therapy, was achieved in 92 patients (77.3%). Only one patient had persistent structural disease. During follow-up, 3/118 patients (2.5%) developed structural recurrence. In the last assessment, 102/115 patients who were not subjected to any additional therapy had nonstimulated Tg up to 0.2 ng/ml, negative antithyroglobulin antibodies, and ultrasonography with no anomalies. No death occurred because of the tumor.

CONCLUSIONS

Postoperative nonstimulated Tg up to 2 ng/ml had a negative predictive value of 98% for recurrent or persistent structural disease. In patients with PTC who have a lower risk of recurrence and who remain with nonstimulated Tg of at least 0.3 ng/ml after total thyroidectomy, Tg up to 2 ng/ml can be used as a criterion for ablation with low 131I activity.

摘要

目的

本研究评估了低碘-131(¹³¹I)活度消融术对复发风险较低且全甲状腺切除术后非刺激状态下甲状腺球蛋白(Tg)至少为0.3 ng/ml的甲状腺乳头状癌(PTC)患者的长期疗效。

方法

这是一项前瞻性研究,纳入了119例PTC患者(不包括局限于甲状腺的微小癌以及具有广泛甲状腺外扩展、侵袭性组织学、广泛淋巴结受累或已知残留疾病的肿瘤)。全甲状腺切除术后,所有患者的非刺激状态下Tg至少为0.3 ng/ml(范围:0.3 - 8.5 ng/ml)。患者接受低¹³¹I活度(30或50 mCi)治疗。

结果

治疗后全身扫描显示2例患者有异位摄取。在消融术后12个月评估时,92例患者(77.3%)实现了非刺激状态下Tg高达0.2 ng/ml、抗甲状腺球蛋白抗体阴性且颈部超声检查正常,定义为对初始治疗反应极佳。仅1例患者有持续性结构病变。随访期间,118例患者中有3例(2.5%)发生结构复发。在最后一次评估中,115例未接受任何额外治疗的患者中有102例非刺激状态下Tg高达0.2 ng/ml、抗甲状腺球蛋白抗体阴性且超声检查无异常。无患者因肿瘤死亡。

结论

术后非刺激状态下Tg高达2 ng/ml对复发或持续性结构病变的阴性预测值为98%。对于复发风险较低且全甲状腺切除术后非刺激状态下Tg至少为0.3 ng/ml的PTC患者,Tg高达2 ng/ml可作为低¹³¹I活度消融术的标准。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验